SLC37A2

Across TCGA pan-cancer cohorts, SLC37A2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC37A2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SLC37A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC37A2 expression acts as an unfavorable survival marker.

SKCM, BRCA, and CESC are the cancer types where SLC37A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.029	0.691	<.001	30	view →
BRCA	OS	Median	II,III,IV	0.335	0.913	<.001	26	view →
CESC	OS	Median	IV	0.095	0.592	.004	14	view →
KIRC	OS	Median	All	0.167	0.655	.038	12	view →
LIHC	DFS	Median	All	0.038	0.553	<.001	12	view →
ESCA	DFS	Median	III,IV	0.103	0.442	.021	6	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC37A2–SKCM (DFS)

Open the SKCM breakdown →